We serve γ-aminobutyric acid CAS:56-12-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Uses: It can reduce blood ammonia and promote brain metabolism.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | White crystal or crystalline powder | Conforms |
| Taste | Slightly bitter | Conforms |
| Assay | 99.0%-101.0% | 99.7% |
| Transmittance | ≥98.0% | 98.0% |
| Chloride（Cl） | ≤0.02% | ＜0.02% |
| Ammonium（NH4） | ≤0.02% | ＜0.02% |
| Sulfate（SO4） | ≤0.048% | ＜0.048% |
| Iron（Fe） | ≤30ppm | ＜30ppm |
| Heavy metal | ≤10ppm | ＜10ppm |
| Arsenic | ≤2ppm | ＜2ppm |
| Other amino acids | Not detected | Not detected |
| Loss on drying | ≤0.50% | 0.16% |
| Residue on ignition | ≤0.10% | 0.04% |
| PH | 7.0-8.0 | 7.35 |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like γ-aminobutyric acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,gamma-aminobutyric acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Butanoic acid, 4-amino- Use and application,Butanoic acid, 4-amino- technical grade,usp/ep/jp grade.
Related News: At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.(R)-1-(4-(3-methylpyrrolidin-1-yl)but-2-yn-1-yl)pyrrolidine-2,5-dione manufacturer At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.Potassium tetracyanonickelate(II) hydrate supplier “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.(Bis-dimethylamino-fluor-phenyl-phosphonium) vendor “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.The best you can do is take medicines and treatments for specific symptoms.
